

Robert S Brown Jr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11339147/publications.pdf>

Version: 2024-02-01

198
papers

17,719
citations

16411

64
h-index

13338

130
g-index

211
all docs

211
docs citations

211
times ranked

15931
citing authors

#	ARTICLE	IF	CITATIONS
1	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. American Journal of Transplantation, 2022, 22, 1925-1926.	2.6	54
2	The Dark Before Dawn. Liver Transplantation, 2022, 28, 533-534.	1.3	0
3	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 2083-2088.	2.6	64
4	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ALH). Liver International, 2022, 42, 1109-1120.	1.9	20
5	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. Journal of Clinical Gastroenterology, 2022, Publish Ahead of Print, .	1.1	2
6	Practices and Perceptions of Living Donor Liver Transplantation, Nondirected Donation, and Liver Paired Exchange: A National Survey. Liver Transplantation, 2022, 28, 774-781.	1.3	5
7	Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infectious Diseases and Therapy, 2022, 11, 913-924.	1.8	1
8	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. American Journal of Transplantation, 2022, 22, 2682-2688.	2.6	35
9	Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. Journal of Intensive Care Medicine, 2021, 36, 524-541.	1.3	11
10	SARS-CoV-2 infection increases tacrolimus concentrations in solid organ transplant recipients. Clinical Transplantation, 2021, 35, e14193.	0.8	14
11	National Trends in Location of Death in Patients With End-Stage Liver Disease. Liver Transplantation, 2021, 27, 165-176.	1.3	13
12	A Review of the Current State of Liver Transplantation Disparities. Liver Transplantation, 2021, 27, 434-443.	1.3	44
13	Hepatology Highlights. Hepatology, 2021, 73, 1-3.	3.6	0
14	Hepatology Highlights. Hepatology, 2021, 73, 475-478.	3.6	0
15	Reply. Liver Transplantation, 2021, 27, 606-606.	1.3	0
16	Hepatology Highlights. Hepatology, 2021, 73, 1245-1247.	3.6	0
17	Hepatology Highlights. Hepatology, 2021, 73, 2085-2088.	3.6	1
18	Dynamic Î±-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surgery, 2021, 156, 559.	2.2	34

#	ARTICLE	IF	CITATIONS
19	Can Living Donor Liver Transplantation in the United States Reach Its Potential?. Liver Transplantation, 2021, 27, 1644-1652.	1.3	10
20	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	1.3	4
21	The Current Management of Hepatorenal Syndrome-“Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transplantation, 2021, 27, 1191-1202.	1.3	23
22	Hepatology Highlights. Hepatology, 2021, 74, 1-4.	3.6	5
23	Hepatology Highlights. Hepatology, 2021, 74, 539-542.	3.6	0
24	Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3363-3370.	1.4	7
25	Hepatology Highlights. Hepatology, 2021, 74, 1137-1140.	3.6	0
26	Protecting Patients With Cirrhosis From Coronavirus Disease 2019: Identifying Gaps in Vaccination Rates. Liver Transplantation, 2021, 27, 1535-1537.	1.3	0
27	Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. Hepatology, 2021, 74, 1523-1532.	3.6	47
28	Hepatology Highlights. Hepatology, 2021, 74, 2329-2332.	3.6	0
29	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	3.6	151
30	Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. Hepatology, 2020, 71, 4-7.	3.6	11
31	Glecaprevir/pibrentasvir for 8-weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. Journal of Hepatology, 2020, 72, 441-449.	1.8	109
32	Patient Perspectives of High-Quality Care on the Liver Transplant Waiting List: A Qualitative Study. Liver Transplantation, 2020, 26, 238-246.	1.3	5
33	The North American Consortium for the Study of End-Stage Liver Disease-“Acute-on-Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. Liver Transplantation, 2020, 26, 187-195.	1.3	25
34	Hepatology Highlights. Hepatology, 2020, 72, 791-793.	3.6	0
35	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687.	3.0	55
36	Hepatology Highlights. Hepatology, 2020, 72, 369-370.	3.6	0

#	ARTICLE	IF	CITATIONS
37	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2307-2315.	1.4	2
38	Hepatology Highlights. <i>Hepatology</i> , 2020, 72, 1893-1896.	3.6	0
39	Hepatology Highlights. <i>Hepatology</i> , 2020, 72, 1505-1508.	3.6	0
40	Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1328-1336.	1.3	6
41	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 771-773.	3.6	0
42	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
43	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 405-407.	3.6	0
44	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 1-3.	3.6	2
45	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 1527-1529.	3.6	0
46	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 1143-1145.	3.6	0
47	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020, 20, 1800-1808.	2.6	683
48	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
49	Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. <i>PLoS ONE</i> , 2020, 15, e0239536.	1.1	33
50	SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. <i>World Journal of Gastroenterology</i> , 2020, 26, 1546-1553.	1.4	46
51	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Current Hepatology Reports</i> , 2019, 18, 363-369.	0.4	0
52	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
53	Hepatology Highlights. <i>Hepatology</i> , 2019, 70, 1497-1499.	3.6	2
54	Opioid epidemic and liver disease. <i>JHEP Reports</i> , 2019, 1, 240-255.	2.6	18

#	ARTICLE	IF	CITATIONS
55	246 "Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. Gastroenterology, 2019, 156, S-1186.	0.6	2
56	Hepatology Highlights. Hepatology, 2019, 69, 469-472.	3.6	0
57	Identifying Risk of Alcohol Relapse After Liver Transplantation: What Tools Do We Need?. Liver Transplantation, 2019, 25, 1133-1135.	1.3	9
58	Hepatology Highlights. Hepatology, 2019, 69, 2311-2314.	3.6	1
59	Hepatology Highlights. Hepatology, 2019, 69, 1365-1368.	3.6	1
60	Hepatology Highlights. Hepatology, 2019, 69, 1849-1851.	3.6	0
61	A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. Hepatology, 2019, 70, 1038-1044.	3.6	13
62	Hepatology Highlights. Hepatology, 2019, 69, 927-930.	3.6	0
63	Hepatology Highlights. Hepatology, 2019, 70, 1881-1884.	3.6	0
64	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	13.7	493
65	Hepatology Highlights. Hepatology, 2019, 69, 1-4.	3.6	18
66	Hepatology Highlights. Hepatology, 2018, 67, 817-819.	3.6	0
67	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology, 2018, 68, 1298-1307.	3.6	158
68	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	1.8	144
69	Hepatology Highlights. Hepatology, 2018, 67, 1647-1650.	3.6	0
70	Hepatology Highlights. Hepatology, 2018, 67, 1195-1197.	3.6	0
71	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67, 1560-1599.	3.6	2,620
72	Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts. Liver Transplantation, 2018, 24, 881-887.	1.3	11

#	ARTICLE	IF	CITATIONS
73	Hepatology Highlights. <i>Hepatology</i> , 2018, 67, 461-463.	3.6	0
74	Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 809-815.	0.5	9
75	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018, 22, 347-360.	1.0	8
76	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018, 38, 1010-1021.	1.9	10
77	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 566-577.	0.8	4
78	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clinical Transplantation</i> , 2018, 32, e13415.	0.8	16
79	Is it Time to Abandon the Milan Criteria?. <i>Annals of Surgery</i> , 2018, 268, 690-699.	2.1	87
80	Reply. <i>Hepatology</i> , 2018, 68, 1658-1660.	3.6	2
81	If hepatitis C therapy is so great, why isn't everyone doing it?. <i>American Journal of Transplantation</i> , 2018, 18, 2382-2383.	2.6	0
82	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. <i>Gastroenterology</i> , 2017, 152, 648-664.e5.	0.6	12
83	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	3.6	149
84	Recurrence After Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 557-564.	2.1	204
85	HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency. <i>Transplantation</i> , 2017, 101, 924-932.	0.5	6
86	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017, 30, 196-208.	0.8	14
87	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017, 13, 154-163.	0.2	1
88	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e60-e64.	1.1	8
89	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	1.3	73
90	Reply. <i>Hepatology</i> , 2016, 64, 1824-1825.	3.6	0

#	ARTICLE	IF	CITATIONS
91	Spontaneous bacterial peritonitis is a risk factor for renal failure requiring dialysis in waitlisted liver transplant candidates. <i>Clinical Transplantation</i> , 2016, 30, 502-507.	0.8	5
92	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	1.3	100
93	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 284-306.	3.6	414
94	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 307-318.	3.6	62
95	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.	3.7	63
96	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	1.9	4
97	Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 903-906.e1.	2.4	47
98	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 319-333.	3.6	275
99	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
100	Reply. <i>Hepatology</i> , 2015, 61, 1439-1439.	3.6	0
101	Reply. <i>Hepatology</i> , 2015, 62, 1328-1329.	3.6	0
102	Hepatitis C Genotype Influences Post-liver Transplant Outcomes. <i>Transplantation</i> , 2015, 99, 835-840.	0.5	19
103	High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015, 35, 510-517.	1.9	16
104	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651.	0.5	19
105	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	0.6	725
106	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , 2015, 373, 2618-2628.	13.9	692
107	Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). <i>Journal of Hepatology</i> , 2015, 62, 346-353.	1.8	85
108	Current Indications, Contraindications, Delisting Criteria, and Timing For Transplantation. , 2015, , 94-104.		1

#	ARTICLE	IF	CITATIONS
109	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269.	1.4	1
110	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	0.6	317
111	Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 459-68.	0.6	22
112	Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. <i>Hepatology</i> , 2014, 60, 1957-1962.	3.6	110
113	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. <i>Hepatology</i> , 2014, 59, 1073-1083.	3.6	138
114	Steroid use in acute liver failure. <i>Hepatology</i> , 2014, 59, 612-621.	3.6	153
115	Reply. <i>Hepatology</i> , 2014, 60, 1448-1448.	3.6	0
116	Predictors of donor follow-up after living donor liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 967-976.	1.3	13
117	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014, 61, 508-514.	1.8	75
118	Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study. <i>Hepatology</i> , 2014, 59, 1311-1319.	3.6	19
119	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	0.6	51
120	Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors, and prognosis. <i>Liver Transplantation</i> , 2013, 19, 78-88.	1.3	68
121	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013, 57, 1752-1762.	3.6	113
122	Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. <i>Clinical Transplantation</i> , 2013, 27, 829-837.	0.8	9
123	The Hepatitis Aggressiveness Score (HAS). <i>American Journal of Surgical Pathology</i> , 2013, 37, 104-113.	2.1	20
124	Hepatitis C viral infection after liver transplantation. <i>Clinical Liver Disease</i> , 2012, 1, 73-76.	1.0	0
125	Living donor liver transplantation for HCV: Will the true outcomes stand up?. <i>Journal of Hepatology</i> , 2012, 57, 1166-1167.	1.8	2
126	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012, 57, 953-959.	1.8	71

#	ARTICLE	IF	CITATIONS
127	Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: A multicenter cohort study. <i>Liver Transplantation</i> , 2012, 18, 532-538.	1.3	55
128	Basiliximab Induction and Delayed Calcineurin Inhibitor Initiation in Liver Transplant Recipients With Renal Insufficiency. <i>Transplantation</i> , 2011, 91, 1254-1260.	0.5	30
129	Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 720-726.	1.1	18
130	Do Preoperative Inflammatory Markers Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma?. <i>Annals of Surgery</i> , 2011, 254, 383-384.	2.1	2
131	Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. <i>Liver Transplantation</i> , 2011, 17, 409-417.	1.3	53
132	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. <i>Hepatology</i> , 2011, 54, 91-100.	3.6	188
133	Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. <i>Hepatology</i> , 2011, 54, 418-424.	3.6	83
134	Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. <i>Hepatology</i> , 2011, 54, 1313-1321.	3.6	136
135	Sorafenib: Where do we go from here?. <i>Hepatology</i> , 2010, 52, 360-369.	3.6	92
136	Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 55-66.	1.4	73
137	Thrombocytopenia With Abnormal Liver Function Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 920-923.	2.4	0
138	Liver Transplantation: Indications, Preoperative Evaluation and Posttransplantation Management. , 2010, , 1353-1381.		1
139	Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 835-842.	2.5	206
140	Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2009, 104, 1392-1400.	0.2	74
141	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009, 14, 156-160.	0.9	8
142	Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome After Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 250, 141-151.	2.1	351
143	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. <i>Chest</i> , 2009, 135, 1470-1475.	0.4	38
144	The Dilemma of Adult-to-Adult Living Donor Liver Transplantation. , 2009, , 65-89.		0

#	ARTICLE	IF	CITATIONS
145	Live donor liver transplantation: Current status. <i>Current Gastroenterology Reports</i> , 2008, 10, 36-42.	1.1	8
146	Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1357-1365.	1.3	32
147	WIN-R revisited: Response to editorial. <i>Hepatology</i> , 2008, 47, 1427-1427.	3.6	0
148	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , 2008, 48, 196-203.	3.6	239
149	Live Donors in Liver Transplantation. <i>Gastroenterology</i> , 2008, 134, 1802-1813.	0.6	172
150	Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Re-transplanted. <i>Clinics in Liver Disease</i> , 2008, 12, 637-659.	1.0	38
151	Racial Disparities in Utilization of Liver Transplantation for Hepatocellular Carcinoma in the United States, 1998-2002. <i>American Journal of Gastroenterology</i> , 2008, 103, 120-127.	0.2	84
152	Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2992-2998.	0.8	478
153	Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2007, 102, 880-889.	0.2	89
154	Steroids in recurrent hepatitis C following liver transplantation: Pitfall or panacea?. <i>Journal of Hepatology</i> , 2007, 47, 741-743.	1.8	5
155	Improvement in Survival Associated With Adult-to-Adult Living Donor Liver Transplantation. <i>Gastroenterology</i> , 2007, 133, 1806-1813.	0.6	216
156	Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. <i>Hepatology</i> , 2007, 46, 982-990.	3.6	70
157	Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. <i>Hepatology</i> , 2007, 46, 1853-1862.	3.6	367
158	Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. <i>Hepatology</i> , 2007, 46, 971-981.	3.6	289
159	Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 122-129.	1.3	119
160	Hepatitis C Virus and Liver Transplantation. <i>Clinics in Liver Disease</i> , 2006, 10, 919-940.	1.0	93
161	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. <i>Gastroenterology</i> , 2006, 131, 470-477.	0.6	453
162	Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: The Transplant Hepatologist. <i>Journal of Hepatology</i> , 2006, 44, 655-657.	1.8	6

#	ARTICLE	IF	CITATIONS
163	Post Liver Transplantation Management and Complications. , 2006, , 961-974.		2
164	The Current State of Liver Transplantation. Gastroenterology and Hepatology, 2006, 2, 244-246.	0.2	0
165	Role of the Independent Donor Advocacy Team in Ethical Decision Making. Progress in Transplantation, 2005, 15, 298-302.	0.4	14
166	Hepatitis C and liver transplantation. Nature, 2005, 436, 973-978.	13.7	319
167	The Survival Impact of Liver Transplantation in the MELD Era, and the Future for Organ Allocation and Distribution. American Journal of Transplantation, 2005, 5, 203-204.	2.6	88
168	Predictors of Candidate Maturation Among Potential Living Donors. American Journal of Transplantation, 2005, 5, 2549-2554.	2.6	15
169	Kidney and Liver Living Donors: A Comparison of Experiences. Progress in Transplantation, 2005, 15, 185-191.	0.4	33
170	Current Indications, Contraindications, Delisting Criteria, and Timing for Liver Transplantation. , 2005, , 95-114.		5
171	A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C. American Journal of Gastroenterology, 2005, 100, 2453-2462.	0.2	127
172	Liver and intestine transplantation. American Journal of Transplantation, 2004, 4, 81-92.	2.6	56
173	Impact of Adult Living Donor Liver Transplantation on Waiting Time Survival in Candidates Listed for Liver Transplantation. American Journal of Transplantation, 2004, 4, 427-431.	2.6	58
174	Adult Living Donor Liver Transplantation. American Journal of Transplantation, 2004, 4, 458-465.	2.6	69
175	Is the Cost of Adult Living Donor Liver Transplantation Higher Than Deceased Donor Liver Transplantation?. Liver Transplantation, 2004, 10, 467-468.	1.3	9
176	Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure. Annals of Surgery, 2004, 239, 660-670.	2.1	574
177	Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. Liver Transplantation, 2003, 9, 254-259.	1.3	29
178	Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transplantation, 2003, 9, 1028-1035.	1.3	116
179	Financial impact of adult living donation. Liver Transplantation, 2003, 9, S12-S15.	1.3	21
180	Scope of worldwide hepatitis C problem. Liver Transplantation, 2003, 9, S10-S13.	1.3	124

#	ARTICLE	IF	CITATIONS
181	Ethical issues in living donor liver transplantation. <i>Current Gastroenterology Reports</i> , 2003, 5, 26-30.	1.1	15
182	Patients with chronic hepatitis C who have normal ALT: A role for interferon-based therapy?. <i>Current Hepatitis Reports</i> , 2003, 2, 11-16.	0.3	0
183	Analysis of Failure in Living Donor Liver Transplantation: Differential Outcomes in Children and Adults. <i>World Journal of Surgery</i> , 2003, 27, 356-364.	0.8	65
184	Interferon Monotherapy for Dialysis Patients With Chronic Hepatitis C: An Analysis of The Literature on Efficacy and Safety. <i>American Journal of Gastroenterology</i> , 2003, 98, 1610-1615.	0.2	161
185	Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. <i>American Journal of Gastroenterology</i> , 2003, 98, 2521-2527.	0.2	69
186	A Survey of Liver Transplantation from Living Adult Donors in the United States. <i>New England Journal of Medicine</i> , 2003, 348, 818-825.	13.9	475
187	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. <i>American Journal of Transplantation</i> , 2002, 2, 491-500.	2.6	71
188	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <i>Liver Transplantation</i> , 2002, 8, 278-284.	1.3	189
189	Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. <i>Liver Transplantation</i> , 2002, 8, 271-277.	1.3	39
190	Endoscopic Treatment of Patients with Portal Hypertension. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2001, 11, 1-14.	0.6	4
191	Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. <i>Hepatology</i> , 2000, 31, 358-363.	3.6	77
192	Predicting outcome of transplantation for cholestatic liver disease: Child-pugh or mayo risk score?. <i>Liver Transplantation</i> , 2000, 6, 759-761.	1.3	2
193	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, S1-S86.	3.0	514
194	Predictors of the cost of liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 170-176.	1.9	58
195	Payer status, but not race, affects the cost of liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 370-377.	1.9	26
196	The Impact of Surgical Complications After Liver Transplantation on Resource Utilization. <i>Archives of Surgery</i> , 1997, 132, 1098.	2.3	50
197	OUTCOME OF PATIENTS WITH RENAL INSUFFICIENCY UNDERGOING LIVER OR LIVER-KIDNEY TRANSPLANTATION1,2. <i>Transplantation</i> , 1996, 62, 1788-1793.	0.5	146
198	HCV and Liver Transplantation. <i>Current Hepatology Reports</i> , 0, , 1.	0.4	0